Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/5/2024 | $180.00 | Perform → Outperform | Oppenheimer |
6/25/2024 | $156.00 → $175.00 | Hold → Buy | TD Cowen |
5/31/2024 | $200.00 | Buy | Stifel |
12/20/2023 | $150.00 | Buy | Jefferies |
6/14/2023 | $89.00 | Neutral | Credit Suisse |
4/5/2023 | Outperform → Perform | Oppenheimer | |
4/4/2023 | $151.00 → $108.00 | Overweight → Equal-Weight | Morgan Stanley |
4/3/2023 | Outperform → Neutral | Credit Suisse |
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
6-K - Ascendis Pharma A/S (0001612042) (Filer)
TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to
TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company. All matters presented for shareholder approval at the Me
Oppenheimer upgraded Ascendis Pharma from Perform to Outperform and set a new price target of $180.00
TD Cowen upgraded Ascendis Pharma from Hold to Buy and set a new price target of $175.00 from $156.00 previously
Stifel initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $200.00
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD). "The sBLA submission for TransCon hGH for adult GHD supports our strategy to develop SKYTROFA into a blockbuster product through label expansion and build upon our value leadership position in the U.S. growth hormone market," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive
COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) shared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon™ PTH (palopegteriparatide; marketed as YORVIPATH®) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population.1,2,3,4 In contrast, these results suggest that long-term palopegterip
COPENHAGEN, Denmark, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares ("ADSs"), each of which represents one ordinary share of Ascendis, at a price to the public of $150.00 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 23, 2024, subject to the satisfaction of customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 300,000 ADSs at the public offering price, less the underwriting commissions. Ascendis estimates the net proceeds from
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 43.24% on an annualized basis producing an average annual return of 54.04%. Currently, Ascendis Pharma has a market capitalization of $7.92 billion. Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 10 years ago, it would be worth $74,821.62 today based on a price of $138.57 for ASND at the time of writing. Ascendis Pharma's Performance Over Last 10 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automa
With U.S. stock futures trading higher on Friday morning, some of the stocks that may grab investor focus today are as follows: Arkhouse Management and Brigade Capital Management increased their offer to buy Macy’s, Inc. (NYSE:M) to $24.80 per share up from the previous bid of $24 per share, the Wall Street Journal reported. Macy’s shares gained 1.2% to $18.14 in the after-hours trading session. Pendopharm signed an exclusive distribution agreement with Ascendis Pharma A/S (NASDAQ:ASND) for TransCon™ PTH in Canada. Ascendis Pharma shares fell 1.5% to close at $134.18 on Wednesday. LGI Homes, Inc. (NASDAQ:LGIH) said it closed 571 homes in June. The company announced plans to release
Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis' hypoparathyroidism treatment TransConTM PTH (palopegteriparatide) in Canada. Financial terms of the agreement are not disclosed.
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated a change from baseline AGV superior to placebo with LS mean treatment difference of 1.78 cm/year at Week 52 (p<0.0001) – Other endpoints supportive that TransCon CNP may provide benefits beyond linear growth – TransCon CNP was generally well-tolerated, with low frequency of injection site reactions (0.41 events per patient year), all mild – Ascendis to host investor conference call Monday, September 16, at 8:00 a.m. E.T. COPENHAGEN, Denmark, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma
NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Ascendis Pharma A/S (NASDAQ:ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath. "We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, as we launch Yorvipath in the U.S. as the first and only FDA approved treatment of hypoparathyroidism in adults," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "This transa
COPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) and Royalty Pharma plc (NASDAQ:RPRX) today announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH. "We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, as we launch YORVIPATH in the U.S. as the first and only FDA approved treatment of hypoparathyroidism in adults," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "This trans